Why might oncologists prefer a second stem cell transplant (SCT) over CAR-T cell therapy for a myeloma relapse?
CAR-T cell therapy has specific eligibility requirements that may limit when it can be used. To qualify for the FDA-approved CAR-T therapy, you need to have already tried at least four other treatments Show Full Answer
Why might oncologists prefer a second stem cell transplant (SCT) over CAR-T cell therapy for a myeloma relapse?
CAR-T cell therapy has specific eligibility requirements that may limit when it can be used. To qualify for the FDA-approved CAR-T therapy, you need to have already tried at least four other treatments, including:
- Immunomodulatory drugs
- Proteasome inhibitors
- Anti-CD38 monoclonal antibodies
Your myeloma also needs to be either refractory (resistant to treatment) or relapsed after previous therapies.
If you relapsed more than six months after your first treatment, your doctor may recommend using that same therapy approach again, which could include another SCT. This timing guideline often influences treatment decisions.
Additionally, CAR-T cell therapy requires specialized treatment centers, can take up to three weeks to prepare, and often requires weeks of hospitalization afterward. Nearly every participant in clinical trials experienced side effects, some potentially serious.
Your oncologist will consider your overall health, how well previous treatments worked, how long you were in remission, and which treatments you've already tried when recommending either a second SCT or CAR-T therapy.
November 4, 2025
Join
Your Privacy Choices
